Ovarian Cancer

Latest News

BMI graphic | Image Credit: Vitalii Vodolazskyi - stock.adobe.com
Overweight-to-Obese Trajectory in Adulthood May Raise Ovarian Cancer Risk

April 22nd 2025

Individuals who transition from overweight to obese during adulthood may face a higher ovarian cancer risk, highlighting the importance of tracking body fat changes.

CA-125 test | Image Credit: jarun011 - stock.adobe.com
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays

April 17th 2025

Patient taking survey | Image Credit: terovesalainen - stock.adobe.com
EHR-Based Symptom Inventory Shows Potential for Ovarian Cancer Monitoring

April 15th 2025

Ovarian cancer animation | Image Credit: Dr_Microbe - stock.adobe.com
Sociodemographic Factors Impact Cytoreductive Surgery Decisions in Advanced Ovarian Cancer

April 9th 2025

Woman stepping on scale | Image Credit: Hunterframe - stock.adobe.com
Obesity May Increase Surgical Complications in Epithelial Ovarian Cancer

April 3rd 2025

Ovarian Cancer Guideline Updates 2024

Ronald D. Alvarez, MD, MBA, analyzes recent changes to NCCN guidelines for ovarian cancer care and provides updates on the latest clinical trial data.

Ronald D. Alvarez, MD, MBA, analyzes recent changes to NCCN guidelines for ovarian cancer care and provides updates on the latest clinical trial data.

More News

MIRASOL: Mirvetuximab Soravtansine Improves PFS, OS in Certain Women With Recurrent Ovarian Cancer
June 4th 2023

MIRASOL: Mirvetuximab Soravtansine Improves PFS, OS in Certain Women With Recurrent Ovarian Cancer

Mary Caffrey
The confirmatory trial showed limited side effects relative to physician's choice of chemotherapy.
ELAHERE logo
April 26th 2023

SORAYA Data Shed Light on Responses to Mirvetuximab Soravtansine Based on Prior Bevacizumab Exposure

AJMC Staff
The antibody drug conjugate received FDA approval in November 2022.
Neil Iyengar, MD
February 21st 2023

Neil Iyengar, MD, Emphasizes Importance of Population Health Lens in Oncology

Hayden E. Klein
FDA Approves Mirvetuximab Soravtansine-gynx for Platinum-Resistant Ovarian Cancer
November 15th 2022

FDA Approves Mirvetuximab Soravtansine-gynx for Platinum-Resistant Ovarian Cancer

Laura Joszt, MA
In addition to the drug approval, the FDA approved a companion diagnostic to be used to identify patients who are eligible to receive the treatment.
Ovarian cancer graphic
February 15th 2021

Proximity to Treatment, Racial Disparities Are Seen in Ovarian Cancer Survival

Maggie L. Shaw
Patients with ovarian cancer who lived within 10 miles of Kansas’s only National Cancer Institute–designated cancer center, and those of a non-White race, were shown to have less of a survival advantage.
Doctor-patient consult
February 11th 2021

Choice of Ovarian Cancer Surgery Influenced by Risk Perception

Maggie L. Shaw
An investigation of 24 women from the United Kingdom’s PROTECTOR trial has revealed that their concerns toward cancer risk and menopause affect their choice of surgery as treatment for ovarian cancer.
Dr Whitney Goldsberry on Cost-Sharing Trends in PARP Inhibitors for Ovarian Cancer
February 6th 2021

Dr Whitney Goldsberry on Cost-Sharing Trends in PARP Inhibitors for Ovarian Cancer

Whitney Goldsberry, MD, fellow at the University of Alabama's Division of Gynecologic Oncology, discusses findings from her and colleagues' recent analysis of cost-sharing trends for PARP inhibitors in ovarian cancer treatment.
Laparoscopy Shown to Be Cost-effective in Evaluating Newly Diagnosed Ovarian Cancer
February 5th 2021

Laparoscopy Shown to Be Cost-effective in Evaluating Newly Diagnosed Ovarian Cancer

AJMC Staff
Researchers from MD Anderson Cancer Center found that laparoscopy cost more upfront but eliminated wasteful treatment decisions.
Recent Adavosertib Results in Ovarian Cancer Could Be Sign of Things to Come
January 30th 2021

Recent Adavosertib Results in Ovarian Cancer Could Be Sign of Things to Come

Mary Caffrey
Recent results with adavosertib in ovarian cancer could signal future positive results, given the number of trials using the targeted therapy with the PARP inhibitor olaparib.
Site Logo
January 20th 2021

Lauren M. Corduck, Founder of Oneinforty, Dies at 49; Advocated for Change in BRCA Testing Guidelines

Mary Caffrey
Lauren M. Corduck, who turned a diagnosis of ovarian cancer into a crusade to educate others with similar genetic mutations, died on December 24, 2020. She was 49.
Older Patient Consulting With Doctor
January 15th 2021

Aggressive Treatment Might Benefit Older Patients With Ovarian Cancer

Rose McNulty
Certain elderly women with ovarian cancer might benefit from aggressive treatment methods, a study recently published in Annals of Surgical Oncology found.
Jessica Greenwood, MS
January 15th 2021

Payer Coverage Is the Key to Cost-effective Panel Testing in Gynecological Cancers

Mary Caffrey
Panel testing for genetic variants linked to more cancers is cost-effective than just testing or BRCA1/2 mutations, says a clinical director for a women's health company.
Daniel F. Hayes, MD
January 9th 2021

What Is Clinical Utility in a Tumor Biomarker Test? Former ASCO President Knows It When He Sees It

Mary Caffrey
Daniel F. Hayes, MD, offers definitions and an algorithm for clinicians to define clinical utility.
women pain
January 9th 2021

Study Finds Link Between Larger Endometriomas and Ovarian Cancer

AJMC Staff
A study links the size of cysts associated with endometriosis with coexistent ovarian cancer.
Dr Bradley Monk Discusses Indications for PARP Inhibitors in Ovarian Cancer
December 30th 2020

Dr Bradley Monk Discusses Indications for PARP Inhibitors in Ovarian Cancer

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, describes the current indications for PARP inhibitors in ovarian cancer.
Bradley Monk, MD
December 28th 2020

Dr Bradley Monk on Response to PARP Inhibitors in Ovarian Cancer

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, discusses the ovarian cancer patients most likely to respond well to PARP inhibition.
Bradley Monk, MD
December 26th 2020

Dr Bradley Monk on the Changing Regulatory Landscape of PARP Inhibitors

Rose McNulty
Bradley Monk, MD, FACOG, FACS, a professor at the University of Arizona, chronicles the regulatory changes in PARP inhibitors as they gain more indications in ovarian cancer.
Bradley Monk, MD
December 24th 2020

Dr Bradley Monk on Multidisciplinary Care With PARP Inhibitors

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, shares his experience mitigating the potential side effects of PARP inhibitors in ovarian cancer treatment.
Bradley Monk, MD, FACOG, FACS
December 18th 2020

Dr Bradley Monk Discusses PARP Inhibitor Reimbursement

Rose McNulty
Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, professor at the University of Arizona and Creighton University in Phoenix, discusses the reimbursement of PARP inhibitors in ovarian cancer.
Ovarian Cancer
December 11th 2020

Novel Combination Shows Promise in Recurrent Ovarian Cancer

Rose McNulty
A combination of pembrolizumab with bevacizumab and cyclophosphamide showed clinical activity and tolerability in patients with recurrent ovarian cancer, a small study found.
Teal ovarian cancer awareness ribbon
December 10th 2020

Top-line Phase 1 Results for Cantrixil Confirm Earlier Efficacy, Safety Signals

AJMC Staff
Kazia Therapeutics will report the full results at a future scientific meeting.
Phase 1 Study of Novel Drug for Ovarian Cancer Shows Positive Results
December 5th 2020

Phase 1 Study of Novel Drug for Ovarian Cancer Shows Positive Results

AJMC Staff
One patient had a complete response and the majority of patients achieved disease control at 12 weeks.
Discussion of Ovarian Cancer Risk
December 4th 2020

Assisted Reproductive Technology Does Not Increase Ovarian Cancer Risk

Rose McNulty
New findings in Journal of the National Cancer Institute contradict previous research indicating that assisted reproductive technology might lead to an increased risk of ovarian cancer.
Study Examines Impact of Tumor Mutational Burden on Ovarian Cancer
November 25th 2020

Study Examines Impact of Tumor Mutational Burden on Ovarian Cancer

Allison Inserro
Tumor mutational burden is an emerging biomarker to predict response to immune checkpoint inhibitors, but its utility as a prognostic indicator in ovarian cancer is unclear.
Small Study Finds Potential Risk of Hematologic Abnormalities After Ovarian Cancer Treatment
November 24th 2020

Small Study Finds Potential Risk of Hematologic Abnormalities After Ovarian Cancer Treatment

Jared Kaltwasser
The new report suggests that patients treated with prolonged poly-ADP-ribose polymerase inhibitors after chemotherapy may need close hematological monitoring.
Patients With Ovarian Cancer Struggle With Uncertainty, Fears of Future, Study Finds
November 23rd 2020

Patients With Ovarian Cancer Struggle With Uncertainty, Fears of Future, Study Finds

Jared Kaltwasser
The dearth of effective treatment options for patients with ovarian cancer not only leads to poor health outcomes, but also leads to psychological distress, according to new research.
Ovarian tumor graphic
November 19th 2020

Review Offers First Head-to-Head Look at PARP Inhibitors for Ovarian Cancer

Jaime Rosenberg
Drawing on data from 6 randomized controlled trials accounting for over 2200 patients, the researchers the researchers compared the efficacy and safety of olaparib, rucaparib, and niraparib.
Careful Observation of Ovarian Cysts Safe Alternative to Surgery
February 9th 2019

Careful Observation of Ovarian Cysts Safe Alternative to Surgery

Samantha DiGrande
Once identified, ovarian tumors are usually surgically removed due to the presumed risk of complications associated with the diagnosis. Researchers recently looked to evaluate the incidence of cyst complications and malignancy during the first 2 years of follow-up after the tumors were classified as benign.
Dr John Schorge Discusses Prevention Methods in Ovarian Cancer
June 30th 2018

Dr John Schorge Discusses Prevention Methods in Ovarian Cancer

John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses different prevention methods in ovarian cancer.
Site Logo
August 18th 2017

Expanded Approval, New Dosage Form for Olaparib in Recurrent Ovarian Cancer

Surabhi Dangi-Garimella, PhD
A new oral dosage form of olaparib (Lynparza) has been approved as maintenance treatment in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
<123456>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo